ACN Newswire
HONG KONG, Aug 14, 2025 – (ACN Newswire) – Everest Medicines (HKEX 1952.HK, “Everest”) today announced that the Taiwan Food and Drug Administration (TFDA) has officially accepted the New Drug Application (NDA) for VELSIPITY(R) (etrasimod) for the treatment of patients with moderately to severely active ulcerative colitis (UC).Building on prior approvals in Singapore…
Read More
Everest Medicines’ New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access
Tomi Kucera
16:20
HONG KONG, Aug 14, 2025 – (ACN Newswire) – Everest Medicines (HKEX 1952.HK, “Everest”) today announced that the Taiwan Food and Drug Administration (TFDA) has officially accepted the New Drug Application (NDA) for VELSIPITY(R) (etrasimod) for the treatment of patients with moderately to severely active ulcerative colitis (UC).Building on prior approvals in Singapore…
